<DOC>
	<DOCNO>NCT00055497</DOCNO>
	<brief_summary>The objective : ( 1 ) To demonstrate efficacy adalimumab maintenance clinical remission 56 week participants Crohn 's disease participate NCT00055523 ; ( 2 ) To delineate safety adalimumab administer participant Crohn 's disease 56 week .</brief_summary>
	<brief_title>Remission Subjects With Crohn 's Disease , 1 Year Phase</brief_title>
	<detailed_description>Study NCT00055497 design evaluate efficacy safety adalimumab maintenance clinical remission patient Crohn 's disease ( CD ) . The study consist 2 phase : 1. first year phase last Week 56 consist randomize , double-blind ( DB ) , placebo-controlled portion ( NCT00055497 ) concomitant open label ( OL ) portion , 2. long-term extension phase ( NCT01070303 ) last 264 additional week ( Week 56 Week 320 ) . Potential participant screen time enrollment lead-in , induction therapy study ( NCT00055523 ) . Participants complete lead-in study , NCT00055523 , eligible participate rollover study , NCT00055497 . In Study NCT00055497 , participant receive 40 mg adalimumab subcutaneously ( SC ) Baseline ( Week 0 ) Week 2 Study NCT00055497 . Baseline Study NCT00055497 synonymous NCT00055523 Week 4 . At Week 4 Study NCT00055497 , participant randomize base clinical remission status Baseline Week 4 Study NCT00055497 . Participants demonstrate clinical remission ( define Crohn 's Disease Activity Index [ CDAI ] score &lt; 150 point ) Baseline Study NCT00055497 remain clinical remission Week 4 Study NCT00055497 ( participant constitute randomized analysis set ) randomize receive 1 3 blind treatment : adalimumab 40 mg every week ( eow ) , adalimumab 40 mg every week ( ew ) , placebo . Participants demonstrate clinical remission Baseline Study NCT00055497 , longer clinical remission Week 4 Study NCT00055497 assign receive OL adalimumab 40 mg eow ; participant constitute OL analysis set . At time Study NCT00055497 , participant receive OL adalimumab 40 mg SC eow develop flare non-responders OL treatment could his/her dose increased 40 mg SC weekly . Participants document complete Week 56 count study completion total . After 1 year ( Week 56 ) , participant meet eligibility criterion long-term extension phase ( NCT01070303 ) switch OL adalimumab 40 mg subcutaneous ( SC ) eow , participant previously OL treatment group Study NCT00055497 continue previous OL adalimumab dose ( adalimumab 40 mg SC eow every week ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion : Patient must successfully complete induction study NCT00055523 Diagnosis Crohn 's disease Willing able give inform consent Exclusion : Diagnosis ulcerative colitis Pregnancy breastfeed Previous use infliximab antiTNF antagonists Previous history active tuberculosis listeria infection Previous history cancer successfully treat skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>